GDC-0339 is primarily investigated for its potential therapeutic applications in the field of oncology, particularly for cancers with KRAS mutations. It functions as a potent and selective inhibitor of KRAS protein, which plays a critical role in cancer cell proliferation and survival. By targeting KRAS, GDC-0339 aims to disrupt signaling pathways that are often dysregulated in various types of cancers, thereby inhibiting tumor growth and progression. Preclinical studies have shown promising results in reducing tumor size and improving survival rates in animal models. Its application is being explored in combination with other anticancer therapies to enhance efficacy and overcome drug resistance. Ongoing research focuses on its potential use in treating solid tumors and hematologic malignancies, with clinical trials underway to evaluate its safety and effectiveness in human patients.